

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Robert Madsen on 8/25/09.

The application has been amended as follows:

In claim 2, line 5, please change the word "comprising" to "consisting of".

In claim 2, line 8, please change the word "comprising" to "consisting of".

In claim 15, line 7, please change the word "comprising" to "consisting of".

In claim 15, line 10, please change the word "comprising" to "consisting of".

The following is an examiner's statement of reasons for allowance: The prior art does not teach or suggest the subject matter recited in the claims. See Applicant's arguments of 8/12/09. The prior art teaches either structural studies of Rho GTPase activators or genomic studies of bacteria having Rho GTPase activators. None of these documents describe vaccine composition resulting from the specific combination of (i) **an antigen and (ii) a RhoGTPase activator (wherein the Rho GTPase activator is selected from the group consisting of: a polypeptide set forth in SEQ ID NO: 1 or 4; or a polypeptide consisting of amino acids 720-1014 of SEQ ID NO: 1 or polypeptide consisting of amino acids 1146-1451 of SEQ ID NO: 4)** as an

immunoadjuvant. None of these cited documents deal with vaccination and, thus, fail to suggest that Rho GTPase activator has immunoadjuvant properties. Applicants unexpectedly found that these regulatory proteins contained immunoadjuvant-like properties.

2. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Correspondence regarding this application should be directed to Group Art Unit 1645. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Remsen. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The Group 1645 Fax number is 571-273-8300 which is able to receive transmissions 24 hours/day, 7 days/week.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer E. Graser whose telephone number is (571) 272-0858. The examiner can normally be reached on Monday-Thursday from 8:00 AM-6:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert Mondesi, can be reached on (571) 272-0956.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-0500.

/Jennifer E. Graser/
Primary Examiner, Art Unit 1645

Application/Control Number: 10/589,505
Art Unit: 1645

Page 4

8/26/09